Halozyme Announces Global Collaboration and License Agreement with GSK to Develop Subcutaneous Formulations of Multiple Promising Oncology Targets
Go back to Halozyme Announces Global Collaboration and License Agreement with GSK to Develop Subcutaneous Formulations of Multiple Promising Oncology Targets| Halozyme Therapeutics, Inc. (NASDAQ: HALO) | Delayed: 70.13 +1.14 (1.65%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $68.99 | 52 Week High | $18.39 | |||
| Open | $69.38 | 52 Week Low | $6.96 | |||
| Day High | $70.21 | P/E | N/A | |||
| Day Low | $68.93 | EPS | $-0.58 | |||
| Volume | 475,649 | |||||
